Zacks Investment Research upgraded shares of INTEGRA LIFESCI (IART) from UNDERPERFORM to NEUTRAL on June 11, 2013, with a target price of $37.80.
Integra LifeSciences Corp. develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of burns and skin defects, spinal and cranial disorders, orthopedics and other surgical applications. Integra seeks to be the world's leading company specializing in implantable medical and biopharmaceutical therapies to target and control cell behavior, and to build shareholder value by acquiring, discovering, and developing cost-effective, off-the-shelf products that satisfy unmet medical needs.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on INTEGRA LIFESCI (IART),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment